Navigation Links
New study shows SARS can infect brain tissue

Severe acute respiratory syndrome (SARS), by its very name, indicates a disease of the respiratory tract. But SARS can also infiltrate brain tissue, causing significant central nervous system problems, according to an article in the Oct. 15 issue of Clinical Infectious Diseases, now available online.

SARS, a potentially fatal illness caused by a coronavirus, was first reported in Asia in February of 2003. The disease is usually transmitted by contact with coronavirus-laden droplets sprayed into the air by an infected person's coughing. Other symptoms can include high fever, headache, body aches, and pneumonia. However, some patients also exhibit central nervous system ailments. In a new study, the researchers report the case of a 39-year-old doctor who treated SARS patients in China during the 2003 outbreak and became infected himself.

He showed the usual symptoms of SARS--fever, chills, headache, muscle pain--but after hospitalization, he developed vision problems, then progressively worse central nervous system symptoms, like restlessness and delirium. A computed tomography scan indicated brain damage. He died about a month after being hospitalized, and his brain tissue was examined and found to contain the SARS coronavirus. The researchers also discovered a high level of Mig, a type of immune system regulator called a chemokine, in the man's bloodstream and brain, which may have resulted from the central nervous system infection. The researchers speculated that Mig could also have contributed to his brain damage by attracting immunological cells to the site of the viral infection in the brain, where their inflammatory effects may have done more harm than good.

There are a few possibilities for curbing Mig's possible role in causing brain damage in SARS patients with central nervous system infection, according to lead author Jun Xu, PhD, of the Guangzhou Institute of Respiratory Diseases and senior author Yong Jiang, PhD, of the Key Laborat
'"/>

Source:Infectious Diseases Society of America


Page: 1 2

Related biology news :

1. Bioartificial kidney under study at MCG
2. W.M. Keck Foundation funds study of friendly microbes
3. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
4. Genome-wide mouse study yields link to human leukemia
5. Clam embryo study shows pollutant mixture adversely affects nerve cell development
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Same mutation aided evolution in many fish species, Stanford study finds
8. Sequencing of marine bacterium will help study of cell communication
9. Genetically modified rice in China benefits farmers health, study finds
10. A new study examines how shared pathogens affect host populations
11. NYU study reveals how brains immune system fights viral encephalitis

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New study shows SARS can infect brain tissue

(Date:11/4/2009)...ver, BC - Lowly bacteria, it turns out, hold the p...g plants around the world clean up toxic waste on ...cifically RDX, were invented back in World War II ...es. These high-energy compounds are often used to...ersion of TNT. , But with increased knowledge ...
(Date:11/4/2009)...RTOLA VALLEY, Calif., Oct. 19 Spec...ular sensing and imaging devices which shed light ... it has signed exclusive distribution deals for bo...s. The markets covered include Australia, New Zea...ux), Suriname, Italy, France, Spain, Portugal, Pol...
(Date:11/4/2009)...DFORD, Mass., Oct. 20 Aw...broadband technology and biometrics software, toda...r ended September 30, 2009. ,, Michael Tzanne...aid, "Earlier today, we announced an agreement to ...Lantiq, a new fabless semiconductor company being ...
Breaking Biology News(10 mins):Genomic research will enable greener cleanup of military explosive test sites 2Spectros Signs New International Distribution Deals 2Aware, Inc. Reports Third Quarter 2009 Financial Results 2Aware, Inc. Reports Third Quarter 2009 Financial Results 3Aware, Inc. Reports Third Quarter 2009 Financial Results 4Aware, Inc. Reports Third Quarter 2009 Financial Results 5Aware, Inc. Reports Third Quarter 2009 Financial Results 6Aware, Inc. Reports Third Quarter 2009 Financial Results 7United States Patent and Trademark Office Accepts CoolTouch 26apos 3Bs Re examination Request for Cynosure 26apos 3B873 Patent 47571 1United States Patent and Trademark Office Accepts CoolTouch 26apos 3Bs Re examination Request for Cynosure 26apos 3B873 Patent 47571 2Resource for Those Living with Hepatitis C Announces Website Redesign 47569 1Resource for Those Living with Hepatitis C Announces Website Redesign 47569 2Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market 12402 1Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market 12402 2Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market 12402 3
...t the Georgia Institute of Technology have used a ...e expression of the bacterium that causes anthrax,... 20, 2009, online by the Journal of Bacteriology ...the complete collection of mRNAs produced by a bac...prehensively defined, and provides a much more det...
...e. March 19, 2009. No single decision-support sys... management. That thesis is what a recently releas...e publication, Effects of Timber Harvest Following...the type of forest landscape determines the ways f...e. The authors, however, hope that public land man...
...dentified seven new species of bamboo coral discov...f the Papahānaumokuākea Marine National ...ely new genera, a remarkable feat given the broad ...jor category in the classification of organisms, r...sts expect to identify more new species as analysi...
Other Biology News:New technique used to profile anthrax genome 2New technique used to profile anthrax genome 3Research synthesis shines light on several management options after fires in diverse ecosystems 2New deep-sea coral discovered on NOAA-supported mission 2
(Date:11/6/2009)...f., Nov. 6 ,, 3Q09... of Qutenza(TM) E.U. Marketing Authorization to As...ess in commercial readiness activities Expanded m...r, Marketing; and Director, Commercial Operations ...r and Audit Committee chairman , Upcoming 2...
(Date:11/6/2009)... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ...ny") today announced updated results from a Phase ...th sarcomas metastatic to the lung in a poster pre...ology Society Meeting held in Miami Beach, Florida...n, entitled "A Phase II Study of Intravenous REOLY...
(Date:11/6/2009)... The agenda for Arrowhead’s 2010 Persona...et to take place on February 22-24, 2010 in Philad...erence we will highlight key issues in forming par...eir experiences. , Minnea...or Arrowhead’s 2010 Personalized Medicine P...
(Date:11/5/2009)...d., Nov. 5 GenVec, Inc. ...ults for the third quarter ended September 30, 200...04 per share) for the three months ended September...$0.08 per share) in the comparable quarter of 2008...nVec,s net loss was $14.1 million ($0.15 per share...
Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
... Sagent Pharmaceuticals,Inc., a privately-held sp...t it has launched Cefazolin for injection, USP, an...ions. Sagent,s Cefazolin for injection will be,ava...lk package vials.,According to IMS data, sales of ...imately $69 million., The introduction of Cefazol...
...IRFIELD, New Jersey, March 13, "The new Stonegate ... positioned as the only biopharma company that,man...e also having oral and,nasal delivery systems to a...cal" in 2005 with partner Upsher-Smith Laboratorie...ket share of the U.S. nasal calcitonin,market that...
...icromet, Inc.,(Nasdaq: MITI ), a biopharmaceutica...oprietary antibodies for the treatment of cancer, ...ced its financial results for the fourth,quarter a...ult of the,reverse merger between Micromet AG and ... 2006, the financial information included below fo...
Other Biology Technology:Sagent Pharmaceuticals Launches Cefazolin for Injection, USP 2Stonegate Report About Unigene Laboratories Inc. 2Stonegate Report About Unigene Laboratories Inc. 3Stonegate Report About Unigene Laboratories Inc. 4Stonegate Report About Unigene Laboratories Inc. 5Stonegate Report About Unigene Laboratories Inc. 6Stonegate Report About Unigene Laboratories Inc. 7Stonegate Report About Unigene Laboratories Inc. 8Stonegate Report About Unigene Laboratories Inc. 9Stonegate Report About Unigene Laboratories Inc. 10Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results 2Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results 3Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results 4Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results 5Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results 6Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results 7Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results 8Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results 9
Rabbit Anti-EDG2 Polyclonal Antibody, Unconjugated from Abcam
Latex Gloves, PF- small from Santa Cruz Biotechnology, Inc.
GIBCO Dulbecco's Phosphate-Buffered Saline (D-PBS) (1X) liquid from Invitrogen
(Miller's LB Broth Base) Luria Broth Base powder from Invitrogen
Biology Products: